Consumer medicine information

Prostin VR 500 mcg/mL Concentrate for infusion

Alprostadil

BRAND INFORMATION

Brand name

Prostin VR

Active ingredient

Alprostadil

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Prostin VR 500 mcg/mL Concentrate for infusion.

What is in this leaflet


This leaflet answers some common questions about Prostin VR.
It does not contain all the available information and it does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of your child being given Prostin VR against the benefits they expect it to provide your child.
If you have any concerns about your child being given this medicine, ask your doctor or pharmacist.
Keep this leaflet with you.
You may need to read it again.

What Prostin VR is used for


Prostin VR is used to keep a blood vessel called the ductus arteriosis open temporarily after your child is born. Normally this blood vessel closes soon after birth. In some children who are born with heart defects, this blood vessel needs to be kept open for a longer time so that enough blood can reach the rest of the body.
Once the child's heart defect has been fixed or treated, s/he will not usually need to be given Prostin VR any more, and the blood vessel should close.
Your doctor may prescribe Prostin VR for other reasons. Ask your doctor if you have any questions about why Prostin VR has been prescribed for your child.

Before your child is given Prostin VR


Some information is given below. However, always talk to your doctor if you have any concerns or questions about your child's treatment.

When your child must not be given Prostin VR


Children with the following medical conditions must not be given Prostin VR:
  • a blue appearance of the skin, lips and nails due to poor blood flow through the lungs
  • abnormal or unusual blood flow between the lungs and the heart

Before your child is given Prostin VR


Your child should only be given Prostin VR by qualified medical staff. Treatment will normally take place in a hospital because of the need for hospital facilities and skilled personnel.
Tell your doctor if your child is being given any other medicine, including medicines you buy without a prescription from a pharmacy, supermarket or health food shop.
Tell your doctor or pharmacist if your child has had any medical conditions, especially the following:
  • history of bleeding tendencies
  • a breathing problem where the lungs have difficulty holding in air (respiratory distress syndrome).

How Prostin VR is given


Prostin VR will be given to your child by a doctor, nurse, or other trained person. It is diluted and given by continuous infusion into the bloodstream.
Your child's blood pressure will be closely monitored while Prostin VR is being given.

How much is given


Your child's doctor will decide what dose will be given.
Prostin VR Injection is generally not given for more than 2-3 days at a time. It will be given for the shortest time possible to treat your child properly. Treatment courses may be repeated more than once.
Treatment will usually start within 4 days after birth.

Overdose


Overdose is unlikely as treatment will be given by trained medical personnel. Your doctor or pharmacist has information on how to recognise and treat an overdose. The possible side effects of overdose are the same as those listed below under Side Effects.

Side effects


Prostin VR, like all other medicines, may cause unwanted side effects. Sometimes they are serious, often they are not.
Common side effects (occurring in 10-15% of patients) are:

  • Flushing
  • Temporarily stopping breathing
  • Fever

Less common side effects (occurring in less than 10% of patients) include:
  • Slow or fast heart rate
  • Low blood pressure
  • Swelling
  • Heart attack
  • Diarrhoea
  • Fits or convulsions
  • Increased blood clotting
  • Low potassium in the blood
  • Infections

This is not a complete list of side effects. Other side effects not listed above may occur in some patients.
Do not be alarmed by this list of side effects. Your child may not experience any of them.
Ask your doctor to answer any questions you may have.

After using Prostin VR

Storage


Prostin VR will normally be stored in the hospital where it is stored in the refrigerator (2 degrees C to 8 degrees C). Unused ampoules of Prostin VR are stored in the refrigerator. Prostin VR must not be frozen.
After dilution, Prostin VR should be used as soon as possible. If storage is necessary after dilution, then it should be stored in a refrigerator (2°C to 8°C). Any solution not used within 24 hours after dilution should be discarded.

Product description

What it looks like


Prostin VR is a sterile, clear, colourless solution for infusion. It is available in a 500 micrograms/mL strength glass ampoule, and each box contains 5 ampoules.

Ingredients


The active ingredient in Prostin VR is alprostadil (Prostaglandin E1).
Prostin VR also contains ethanol.
Prostin VR does not contain lactose, sucrose, gluten, tartrazine or any other azo dyes.
Prostin VR can be identified by an Australian Registration Number which appears on the box:
AUST R 47641

Supplier


Prostin VR is supplied in Australia by:
Pfizer Australia Pty Ltd
Sydney NSW
Toll Free Number: 1800 675 229
www.pfizer.com.au
This leaflet was revised in October 2019.

BRAND INFORMATION

Brand name

Prostin VR

Active ingredient

Alprostadil

Schedule

S4

 

1 Name of Medicine

Alprostadil (also known as prostaglandin E1).

2 Qualitative and Quantitative Composition

Each 1 mL ampoule contains 500 micrograms alprostadil.
Excipient(s) with known effect. Ethanol.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution for injection.
Prostin VR is a clear, colourless solution.

4 Clinical Particulars

4.9 Overdose

Overdose data is limited. Apnoea, bradycardia, pyrexia, hypotension and flushing may be signs of drug overdose. If apnoea or bradycardia occur, the infusion should be discontinued and the appropriate medical treatment initiated.
There is no antidote for alprostadil overdose. Treatment is symptomatic and supportive. Support respiratory and cardiac function. Monitor pulmonary function, vital signs, ECG and pulse oximetry, and fluid and electrolyte status in patients with significant diarrhoea.
Caution should be used if the infusion is restarted. If pyrexia or hypotension occur, the infusion rate should be reduced until these symptoms subside. Flushing is usually attributed to incorrect intra-arterial catheter placement and is usually alleviated by repositioning the tip of the catheter.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Testicular atrophy and/or degeneration has been observed in rats receiving high doses (10 mg/day for 35 days or longer) of PGE1. The relevance of this to the human neonate is not known.
Carcinogenicity. Long-term carcinogenicity studies have not been done. No potential for mutagenic activity was revealed in assays of gene mutation in bacterial and mammalian cells, or in DNA damage assays; however, alprostadil has not been tested in assays for chromosomal damage.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

The chemical name is (11-a,13E,15S)-11,15-dihydroxy -9-oxoprost-13-en-1-oic acid. The molecular weight of alprostadil is 354.49.
It is a white to off white crystalline powder with a melting point between 110°C and 116°C. Its solubility at 35°C is 8,000 micrograms per 100 mL double distilled water.
Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSALPROS.gif CAS number. 745-65-3.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/PRSTINST.gif